The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: further development of a rodent model of autism spectrum disorders by unknown
RESEARCH Open Access
The enteric bacterial metabolite propionic acid
alters brain and plasma phospholipid molecular
species: further development of a rodent model
of autism spectrum disorders
Raymond H Thomas1*, Melissa M Meeking1, Jennifer R Mepham1, Lisa Tichenoff1, Fred Possmayer2, Suya Liu3
and Derrick F MacFabe1
Abstract
Gastrointestinal symptoms and altered blood phospholipid profiles have been reported in patients with autism
spectrum disorders (ASD). Most of the phospholipid analyses have been conducted on the fatty acid composition
of isolated phospholipid classes following hydrolysis. A paucity of information exists on how the intact
phospholipid molecular species are altered in ASD. We applied ESI/MS to determine how brain and blood intact
phospholipid species were altered during the induction of ASD-like behaviors in rats following intraventricular
infusions with the enteric bacterial metabolite propionic acid. Animals were infused daily for 8 days, locomotor
activity assessed, and animals killed during the induced behaviors. Propionic acid infusions increased locomotor
activity. Lipid analysis revealed treatment altered 21 brain and 30 blood phospholipid molecular species. Notable
alterations were observed in the composition of brain SM, diacyl mono and polyunsaturated PC, PI, PS, PE, and
plasmalogen PC and PE molecular species. These alterations suggest that the propionic acid rat model is a useful
tool to study aberrations in lipid metabolism known to affect membrane fluidity, peroxisomal function, gap junction
coupling capacity, signaling, and neuroinflammation, all of which may be associated with the pathogenesis of ASD.
Keyword: Locomotor activity, Membrane fluidity, Gap junction, Plasmalogens, Docosahexaenoic acid,
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Introduction
Autism spectrum disorders (ASD) are a family of disorders
characterized by stereotypic and restrictive patterns of be-
havior, deficits in social interactions, and impairments in
language development and communication skills [1].
Several recent studies have indicated that interactions be-
tween genetic, metabolic, immunological, gastrointestinal,
environmental, and behavioral factors may be associated
with the pathogenesis of ASD [2-6]. Our research group
has been developing a novel rodent model of autism to
examine enteric bacterial metabolites as possible environ-
mental triggers in ASD. Such a model could prove useful in
investigating how the interactions between the above
factors may contribute to the pathogenesis of ASD [7-12],
and identify potential biomarkers that could be used in
early detection and screening for this disorder.
The central premise of this model is that propionic
acid (PPA) and/or related enteric fatty acids may be can-
didate environmental factors involved in the develop-
ment of some types of ASD. Propionate and other short
chain fatty acids (for example butyrate, acetate) are pro-
duced in the body during normal cellular metabolism
and following enteric bacterial fermentation of dietary
carbohydrates and proteins [13]. PPA producing enteric
bacteria, including unique Clostridial, Desulfovibrio, and
Bacteriodetes species, have been isolated from patients
with regressive ASD [2,14]. Propionate is also present
naturally in a variety of foods and is a common food
preservative in refined wheat and dairy products [15].
Under normal circumstances these short chain fatty
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acids are primarily metabolized in the liver. However, if
there are genetic and/or acquired aberrations in metabol-
ism [7,16], higher than normal levels of short chain fatty
acids can be present in the circulating blood, and can
cross the gut-blood and blood brain barriers passively
and/or actively via high affinity transporters [17]. Under
these conditions, short chain fatty acids can concentrate
intracellularly, particularly in acidotic conditions [18,19],
where they may have deleterious effects on brain develop-
ment and function [13,20,21]. This could be important in
the context of ASD, since PPA is known to affect cell sig-
naling [22], neurotransmitter synthesis and release [20],
mitochondrial function/CoA sequestration [16], lipid me-
tabolism [23] immune function [24], gap junction modula-
tion [19], and gene expression [25], all of which have been
implicated in ASD [7,25-28].
Previous results from our work developing this model in-
dicate that brief, intracerebroventricular infusions with PPA,
but not control compounds (that is, propanol) produced
short bouts of behavioral (hyperactivity, perserveration,
object fixation, social impairments) and electrophysiological
(seizure, caudate spiking) effects, coupled with biochemical
(increased oxidative stress, reduced glutathione) and neuro-
pathological (innate neuroinflammation) alterations in adult
rats, consistent with those seen in ASD [7-11]. Recent find-
ings with this model indicate infusions with PPA or butyrate
altered the brain acylcarnitine and phospholipid profiles
[12]. Interestingly, the alterations in rat brain lipids noted in
this study showed a number of similarities to those docu-
mented in blood from ASD patients [5,29-32].
In the above studies, phospholipid fatty acid compos-
ition was determined by analyzing fatty acid acyl groups
following hydrolysis of the separated phospholipid classes.
Though the standard accepted method of lipid analysis,
this method destroys the phospholipid structure, abolish-
ing the ability to establish the individual phospholipid mo-
lecular species distribution of the samples. Recently, it has
become possible to apply electrospray ionization mass
spectrometry to analyze phospholipids as their intact mo-
lecular species, allowing for identification of individual
and patterns of specific lipids [33-35]. This is potentially
important considering there are presently no reliable bio-
markers for the detection of ASD, the etiology of ASD is
unclear, and altered lipid profiles have been reported both
for ASD patients [5,27,29,32,36] and in the PPA rodent
model of ASD [12]. Therefore, there is a need to deter-
mine: (1) whether or not the intact phospholipid molecu-
lar species are altered in relation to behaviors, to further
validate this animal model; and (2) how these altered
phospholipid profiles may relate to the pathogenesis of
ASD.
The development of liquid chromatography electrospray
ionization mass spectrometry (LC-ESI/MS) has made it pos-
sible to directly analyze phospholipids as intact molecular
species, and preserve the information inherent in their
chemical structure [33,35]. Herein, we used ESI/MS to
determine how the intact blood and brain phospholipid
molecular species are altered during the induction of abnor-
mal (ASD-like) behaviors following PPA infusions in rats.
Materials and methods
Subjects
Twenty four Long-Evans rats (Charles River Laboratories,
Quebec, Canada), weighing 200–225 g (approximately
47–49 days old) at the start of the experiment, were indi-
vidually housed at 21±1°C in standard acrylic cages
(26×48×21 cm) and exposed to 12:12 h light–dark cycle
(lights on 0700 h to 1900 h). Animals were allowed access
to food (Prolab rat chow) and tap water ad libitum. All
procedures were in accordance with guidelines of the
Canadian Council on Animal Care and were approved by the
University of Western Ontario Animal Use Subcommittee.
Surgical implantation of intracerebroventricular (ICV)
cannula
To induce anesthesia, animals were placed in a sealed
Plexiglas box into which 4 % isoflurane and 2 L/min oxy-
gen flow were introduced. The animal was then placed
into a Kopf stereotaxic frame equipped with a gas flow
nose cover to maintain anesthesia throughout surgery at
2 % isoflurane and 500 mL/min oxygen flow. Under asep-
tic conditions, the animal received an implantation of a
23-gauge guide cannula with the tip in the right lateral
ventricle (AP 1.3 mm, ML 1.8 mm, DV 3.0 mm) [37]. Can-
nula placements were in accordance with Paxinos and
Watson [37] rat brain atlas and our previous experience
[7-11]. A removable obturator sealed the guide cannula
until an injection was to be made. To facilitate infusion
into the lateral ventricle, the tip of a 30-gauge injection
cannula protruded 0.5 mm beyond the tip of the guide
cannula. Small stainless steel screws were inserted into the
skull surrounding the cannula to provide anchors for den-
tal acrylic, which attached the cannula to the skull. Imme-
diately post-surgery, all rats received a subcutaneous
injection of analgesic (Ketoprofin, 1 mL/kg). All animals
were allowed 14 days recovery before behavioral testing
took place.
Treatment groups and intracerebroventricular infusion
procedure
Following recovery, animals were assigned to one of two
groups: PPA treatment (4.0 μL of a 0.26 M solution,
n=12), or phosphate buffered saline (PBS) control (4.0 μL,
n=12). Sodium propionic acid was dissolved in PBS ve-
hicle and buffered to pH 7.5 using concentrated HCl. Each
group received intracerebroventricular (ICV) infusions
twice daily, separated by 4 h, for 8 consecutive days. Com-
pounds were infused using a 30-gauge injection cannula
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connected to a Sage syringe pump with sterile PE10 tubing.
The tip of the injection cannula protruded 0.5 mm beyond
the tip of the guide cannula. Each injection consisted of 4.0
μL of solution delivered over a period of 1 min. The infu-
sion cannula remained in place for an additional minute
before being removed.
Apparatus: automated activity monitors
Locomotor activity was monitored using three Versamax
Animal Activity Monitors (AccuScan Model DCM-8,
Columbus, OH, USA). Each monitor consisted of a Plexi-
glas open field chamber (40×40×30.5 cm), and a Plexiglas
lid with air holes. Located on all four sides of the chamber
were 16 infrared beam sensors 2.54 cm apart and 4.5 cm
from the floor to measure horizontal movements and on
two opposite sides were 16 infrared beams located 15 cm
above the chamber floor to measure the vertical move-
ments. Light levels at the floor of each open-field were ap-
proximately 900 lux. A VersaMax Analyser (Accuscan
Model VSA-16, Columbus, OH, USA) processed relayed
data from each automated open-field to a computer located
in an adjacent room to the testing chambers [7,8].
Behavioral testing
The methods used for behavioral assessment presented in
this study have been previously reported (2011) [7-12].
Briefly, animals were habituated to the automated activity
monitors for two 30-min sessions prior to the treatment
sessions. Baseline was recorded on the third day to establish
normal activity levels for untreated animals. Locomotor
assessments were made for 30 min immediately following
the second ICV infusion daily for 7 days. Locomotor activ-
ity was assessed using horizontal, vertical, and repetitive
measures (stereotypy) across infusion days. The horizontal
activity measures analyzed were number of horizontal
movements (the number of horizontal movements sepa-
rated by 1 s stop time), horizontal movement time (length
of time in seconds an animal was engaged in horizontal
movement), and total distance (total horizontal distance
(cm) traveled). The vertical activity measure analyzed was
number of vertical movements (number of vertical move-
ments separated by 1 s stop time). The repetitive activity
measures were: clockwise revolutions (the number of times
an animal ran around in a clockwise circle of at least 2
inches in diameter), counterclockwise revolutions (the
number of times an animal ran around in a counterclock-
wise circle of at least 2 inches in diameter), and the number
of stereotypic movements (repeated breaking of the same
infrared beam separated by 1 s or more). Fifteen minutes
after animals received the final ICV infusion on the eighth
treatment day, they were decapitated, brains quickly
removed, placed on powdered dry ice, then transported
from surgery room to the analytical laboratory for lipid ana-
lysis. Samples were then stored in a −70°C freezer for 2 days
before lipid analysis. Whole blood collected from the
neck following decapitation was heparinized and spun at
3000×g for 5 min, and the supernatant (plasma) collected
for lipid analysis.
Lipid extraction
Brain tissue (100 mg) ipsilateral to ICV infusion site, con-
taining frontal cortex, striatum, thalamus, and dorsal hippo-
campus, 1.3 mm posterior to bregma, [37] was ground to
fine powder while frozen in liquid nitrogen. The ground
brain samples (100 mg) and plasma (100 uL) were transferred
to centrifuge tubes containing a mixture (2.5 mL) of chloro-
form/methanol/0.01 % butylated hydroxytoluene (2:1:0.0003;
v/v/wt) and 100 μL of 1 mg/mL 1,2-dipalmitoyl-sn-glycero-3-
phospho-N,N-dimethylethanolamine (Sigma, St Louis, MO,
USA) added as internal standard. The sample and solvent
mixture was centrifuged at 10,000×g for 15 min. Following
centrifugation, the supernatant was collected and 1 mL of
0.25 % potassium chloride (KCl) was added. The sample was
then incubated in a water bath at 70°C for 10 min. After incu-
bation, the sample was removed, cooled and the aqueous
layer (top) was removed with a Pasteur pipette. The
remaining layer (organic) containing the lipids was transferred
to pre-weighed 4 mL sample vial having a poly-teflon resin
lined cap (VWR). The sample was dried under a gentle
stream of nitrogen and the vial re-weighed to determine the
amount of sample recovered [38,39]. The recovered sample
was then resuspended in 1 mL chloroform:methanol (2:1 v/v)
and stored at −20°C for analysis (ESI/MS).
Electrospray ionization mass spectrometry analysis (ESI-MS)
Aliquots of blood and brain samples were analyzed by in-
fusion on a triple quadruple instrument (Micromass Quat-
troMicro; Waters, Milford. MA, USA) equipped with a
Z-spray source. The mass spectrometer was operated in
both the positive and negative ion modes, and precursor
ion or neutral loss scans specific to the phospholipid
classes were used to determine the composition of the
molecular species of each class [33,40]. Precursor ion scan
(negative mode) of m/z 153 was used to detect all glycero-
phospholipid molecular species, m/z 241 used to detect PI
molecular species (negative mode), precursor ion scan of
m/z 196 (negative mode) or neutral loss scan of 141 D
(positive mode) used to detect PE molecular species, and
neutral loss scan of 87 D (negative mode) or 185 D (posi-
tive mode) used to detect PS molecular species; while pre-
cursor ion scan of m/z 184 in the positive mode was used
to detect SM and PC molecular species. The fatty acid
composition of the identified molecular species of each
phospholipid classes was determined via MS/MS analysis
and reference to the literature (LIPID MAPS). The investi-
gated mass range was from 100–1000m/z. The cone volt-
age was set at 30 V, the collision energy at 30–50 V,
source temperature at 80°C and the collision gas at 2xe-3
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Mbar. Calibration was performed with sodium iodide and
mass error was less than 0.05 Dalton (Da). Flow injection
was carried out with chloroform:methanol:water:ammonia
(20:70:8:2 v/v/v/v) at a flow rate of 50 uL/min with 20 uL
of the sample injected for analysis. Quantitative analysis
was conducted using MassLynx 4.0 software (Micromass)
and Microsoft Excel by using the signal intensity of the
reference standard to normalize the intensities of the iden-
tified molecular phospholipid species after correction for
13C isotope effects. Representative external standards for
each phospholipid classes (Avanti Polar Lipids, Alabaster,
AL, USA) were used to determine the relative amounts of
the molecular species within a phospholipid class. The
amounts of each molecular species within a phospholipid
class are expressed as nanomole percent composition.
Statistical analysis
A total of 24 animals were used for this study (12 PBS
and 12 PPA).
General analysis of variance (ANOVA) was used to deter-
mine the effects of treatments on behavior and phospho-
lipid components. Where treatment effects were significant,
the means were compared with Fisher’s LSD test, α=0.05.
A one-way ANOVA was conducted on the baseline data to
ensure that there were no individual differences in behavior
prior to treatment days. The data were analyzed using the




Locomotor behavior was assessed daily for 7 days, imme-
diately following the second infusion of the day. Prior to
behavioral assessment, there was no significant difference
in baseline behavior between animals assigned to the PPA
and PBS treatment groups. Locomotor activity expressed
by horizontal, vertical, and repetitive measures across infu-
sion days, was used to assess animal behavior. Analysis of
horizontal activity measures revealed a significant effect of
PPA treatment across infusion days for number of hori-
zontal movements, horizontal movement time, and total
distance traveled (Figure 1). Propionic acid treated animals
traveled further, made more horizontal movements, and
spent more time traveling horizontally than PBS treated
animals. The number of horizontal movements was sig-
nificantly higher (F (6, 126)=3.69, P <0.001) in rats infused
with PPA on infusion days 2, 4, 5, 6, and 7 compared to
PBS controls (Figure 1a). A similar pattern was observed
for horizontal movement time (F (6, 126) =2.82, P <0.001)
(Figure 1f) and total distance traveled (F (6, 126)= 2.08,
P <0.001) (Figure 1 g), whereby these behavioral activities
were significantly higher in PPA treated animals compared
to PBS controls on infusion days 2, 3, 4, 5, 6, and 7. Analysis
of the number of vertical movements revealed a significant
(F (6, 126)= 2.82, P <0.001) main effect of PPA treatment
across infusion days, indicating PPA treated animals made
more vertical movements than PBS treated animals on infu-
sion days 3 through 7 (Figure 1b). The results of the repeti-
tive activity measures showed significant increases in
counterclockwise revolutions (F (6, 126)= 2.46, P <0.001),
clockwise revolutions (F (6, 126)= 2.40, P <0.001) and num-
ber of stereotypic movements (F (6, 126)=4.05, P <0.001)
in PPA-treated animals across infusion days. On infusion
days 3, 4, 5, 6, and 7, animals infused with PPA made more
counterclockwise (Figure 1c) and clockwise (Figure 1d)
revolutions than PBS controls. Stereotypy showed a similar
trend whereby PPA-treated animals displayed more stereo-
typic movements than PBS animals on infusions days 2
through 7 (Figure 1e).
Lipid analysis
Behavioral assessment indicated animals developed abnor-
mal (ASD-like) behaviors following PPA infusion (Figure 1).
Animals were killed during the expression of these abnor-
mal behaviors on day 8 and the molecular species of five
phospholipid classes (SM, PC, PI, PS, and PE) were evalu-
ated to determine whether they were altered during the ex-
pression of these behaviors. Phosphatidylcholine and SM
molecular species were detected in the positive ion mode
(Figure 2), while PI, PS, and PE molecular species were
detected in the negative ion mode (Figure 3). Although the
same molecular species for each phospholipid class were
detected in control and PPA-infused animals, the analyses
revealed a quantitative change in these lipid constituents fol-
lowing PPA infusions (Table 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10).
SM molecular species
Sphingomyelin molecular species containing saturated
base (C18:0) and fatty acids predominate in brain sam-
ples (Table 1), while species with monounsaturated base
(C18:1) and polyunsaturated fatty acid predominate in
plasma samples (Table 2).
Propionic acid treatment resulted in alterations in the pro-
portions of both brain (F (27, 56) =10.79, P <0.001) and
plasma (F (27, 56) =32.64, P <0.001) SM molecular species
(Tables 1 and 2). In both brain (Table 1) and plasma
(Table 2) an overall increase (P <0.001) was observed in the
relative level of saturated species, in addition to a reduction
in monounsaturated species. Polyunsaturated species were
unchanged in brain, but increased in plasma following PPA
infusions. Increased proportions (P <0.001) of 36:0 (18:0/
18:0) in brain (Table 1) and 38:0 (18:0/20:0) in plasma
(Table 2) accounted for the increase in saturated SM species.
In brain, the proportions of 38:0 (18:0/20:0) and 40:0 (18:0/
22:0) were decreased, but this had no overall significant ef-
fect on the total brain proportions of saturated SM. Con-
versely, 38:1 (18:1/20:0) in brain (Table 1) and both 34:1
(18:1/16:0) and 38:1 (18:1/20:0) in plasma (Table 2)
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Figure 1 (See legend on next page.)
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accounted for the reduction in monounsaturated SM spe-
cies, while 42:3 (18:1/24:2) in plasma accounted for the
increased polyunsaturated species following PPA infusions
(Table 2).
PC molecular species
Diacyl and plasmalogen PC molecular species were
present in both brain (Table 3) and plasma (Table 4).
However, only the diacyl species were altered (F (59,
120) = 1042.12, P <0.001) in brain following PPA treat-
ments, while both the diacyl and plasmalogen species were
altered (F (59, 120) = 873.32, P <0.001) in plasma. In brain,
the proportions of monounsaturated 34:1 (16:0/18:1) and
polyunsaturated diacyl 34:2 (16:0/18:2) and 36:4 (16:0/
20:4) species were increased; while a reduction was
observed in the monounsaturated diacyl 36:1 (18:0/18:1)
species following PPA treatment (Table 3). No overall
change was observed in the relative proportions of satu-
rated, unsaturated, and polyunsaturated PC species.
Plasma samples on the other hand revealed a reduction in
the level of diacyl polyunsaturated PC species (34:2 (16:0/
18:2), 36:4 (16:0/20:4), 38:2 (18:1/20:1), 38:4 (18:0/20:4)),
and an in increase in the proportions of plasmalogen spe-
cies (36:1 (18:0/18:1)). Although plasma proportions of
diacyl saturated 34:0 (16:0/18:0) and monounsaturated
36:1 (18:0/18:1) molecular species increased following
PPA infusions, this had no effect on the overall level of
total saturated and monounsaturated PC species (Table 4).
m/z









































Scan mode: full ion scan [M+H] +
Scan mode: + prec 184  
[M+H]+ ions of SM + PC
A
IS
Figure 2 Positive ion mass spectra of brain lipid extract. (A) Full ion scan of all lipids present in positive ion mode. (B) Detection of [M+H]+
ions of PC and SM molecular species by precursor scanning of m/z 184. IS, internal standard; PC, phosphatidylcholine; SM, sphingomyelin.
(See figure on previous page.)
Figure 1 Number of horizontal movements (A), number of vertical movements (B), counterclockwise revolutions (C), clockwise
revolutions (D), number of stereotypic movements (E), horizontal movement time (F), and total distance travelled (G), representing
abnormal animal behavior following ICV infusions with PPA and PBS. Animals received ICV infusions of PPA (n= 12) and PBS (n= 12) twice a
day for 7 consecutive days. Behavioral measurements were monitored immediately after each infusion over 30 min. Values represent means ± SE
over 7 days. Bars accompanied by asterisks indicate significant difference between treatments at LSD= 0.05, n= 12 per treatment group. PBS,
phosphate buffered saline solution; PPA, propionic acid.























































































Scan mode: - prec 153  
[M-H]- ions of GPL
Scan mode: - prec 241  
[M-H]- ions of PI
Scan mode: - neutral 87  
[M-H]- ions of  PS
Scan mode: - prec 196 
[M-H]- ions of  PE
Figure 3 (See legend on next page.)
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PI molecular species
Propionic acid treatment altered the proportions of sev-
eral plasma (F (35, 72) = 75.31, P <0.001) PI molecular
species, while the proportions of only two brain (F (35,
72) = 2017.70, P <0.001) PI molecular species were
affected (slightly reduced) (Table 5 and 6). Reduced pro-
portions of polyunsaturated diacyl 36:3 (18:1/18:2) and
40:4 (18:0/22:4) species were observed in brain samples
following PPA treatment (Table 5). The alterations were
more varied with plasma PI molecular species. The pro-
portions of plasma diacyl 34:1 (16:0/18:1), 36:3 (18:1/
18:2), 38:6 (16:0/22:6), 40:4 (18:0/22:4), and 40:6 (18:0/
22:6) increased, while the proportions of the diacyl 38:4
(18:0/20:4) species decreased following PPA treatment
(Table 6). These changes indicate a compositional shift
occurred particularly in plasma PI molecular species fol-
lowing PPA infusions.
PS molecular species
Propionic acid infusions altered the proportions of both
mono and polyunsaturated PS species in brain (Table 7)
and plasma (Table 8). In both brain (F (21, 44) = 305.49,
P <0.001) and plasma (F (21, 44) = 12.14, P <0.001), an
overall increase was observed in the proportion of mono-
unsaturated species, while a reduction was observed in
polyunsaturated species. An increase in brain 36:1 (18:0/
18:1) (Table 7) and plasma (Table 8) 34:1 (16:0/18:1) and
36:1 (18:0/18:1) accounted for the increase in monoun-
saturated PS species. Conversely, a reduction in brain pro-
portions of 40:4 (18:0/22:4) and 40:6 (18:0/22:6) and
plasma proportions of 40:3 (18:0/22:3) and 40:6 (18:0/
22:6) accounted for the reduced polyunsaturated PS spe-
cies following PPA infusions.
PE molecular species
Compositional changes in brain diacyl and plasmalogen
PE species occurred following PPA infusions (Table 9).
Propionic acid treatment reduced (F (79, 160) = 8.79,
P <0.001) P <0.001) brain relative proportions of plasmalo-
gen 40:6 (p18:0/22:6), diacyl polyunsaturated 38:6 (16:0/
22:6), and 40:6 (18:0/22:6) species, but increased the pro-
portions of plasmalogen 36:1 (p18:0/18:1), 36:2 (p18:0/
Table 1 Changes (percent composition) in rat brain
sphingomyelin molecular species following
intraventricular infusion with propionic acid (PPA) and








703 34:1 18:1/16:0 0.07 ± 0.03 0.10 ± 0.05
733 36:0 18:0/18:0 21.96 ± 0.35 39.13 ± 1.35*
731 36:1 18:1/18:0 6.21 ± 0.67 4.53 ± 1.28
761 38:0 18:0/20:0 38.09 ± 0.84 29.37 ±1.92*
759 38:1 18:1/20:0 16.08 ± 0.19 12.31 ± 3.64*
789 40:0 18:0/22:0 13.03 ± 0.24 9.92 ± 1.31*
811 42:3 18:1/24:2 4.56 ± 0.12 4.64 ± 1.54
Total% 100 100
P
Saturates 73.07 ± 0.15 78.41 ±1.44*
P
Monounsat 22.37 ± 0.66 16.94 ±2.91*
P
Polyunsat 4.55 ± 0.12 4.63± 1.54
Values (nanomole percent by weight composition) represent means ± standard
errors. Means in the same row accompanied by asterisks are significantly
different between treatments at LSD= 0.05, n= 12 per treatment group.
Monounsat, monounsaturated fatty acids; PBS, phosphate buffered saline
solution; PPA, propionic acid; polyunsat, polyunsaturated fatty acids.
Sphingomyelin molecular species were identified using a precursor ion scan of
m/z 184 in ESI positive mode. The lipid components in the table are arranged
based on the molecular species composition.
(See figure on previous page.)
Figure 3 Negative ion mass spectra of brain lipid extract. (A) Detection of all [M-H] - ions of glycerophospholipids by precursor ion scan of
m/z 153. (B) Detection of PI molecular species by precursor ion scanning of m/z 241. (C) Detection of PS molecular species by neutrol loss of 87
D. (D) Detection of PE molecular species by precursor ion scanning of m/z 196. GPL, glycerophospholipids; IS, internal standard; PI,
phosphatidylinositol; PS, phosphatidylserine; PE, phosphatidylethanolamine.
Table 2 Changes (percent composition) in rat plasma
sphingomyelin molecular species following
intraventricular infusion with propionic acid (PPA) and








703 34:1 18:1/16:0 14.05 ± 1.42 4.63 ± 1.10*
733 36:0 18:0/18:0 2.63 ± 0.47 3.40 ± 1.23
731 36:1 18:1/18:0 1.54 ± 0.32 1.65 ± 0.42
761 38:0 18:0/20:0 12.91 ± 0.37 15.92 ± 0.65*
759 38:1 18:1/20:0 8.36 ± 0.56 5.77 ± 0.24*
789 40:0 18:0/22:0 9.44 ± 2.89 10.39 ± 2.03
811 42:3 18:1/24:2 51.07 ± 0.62 58.24 ± 0.68*
Total% 100 100
P
Saturates 24.98 ± 1.33 29.72 ±1.49*
P
Monounsat 23.95 ± 1.53 12.05 ±1.57*
P
Polyunsat 51.06 ± 0.63 58.22 ±0.68*
Values (nanomole percent by weight composition) represent means ± standard
errors. Means in the same row accompanied by asterisks are significantly
different between treatments at LSD= 0.05, n= 12 per treatment group.
Monounsat, monounsaturated fatty acids; PBS, phosphate buffered saline
solution; PPA, propionic acid; polyunsat, polyunsaturated fatty acids.
Sphingomyelin molecular species were identified using a precursor ion scan of
m/z 184 in ESI positive mode. The lipid components in the table are arranged
based on the molecular species composition.
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18:2), 38:4 (p18:0/20:4), and 40:4 (p18:0/22:4) molecular
species. In plasma, both the composition and overall rela-
tive proportions of PE diacyl and plasmalogen species
were altered following PPA infusions (Table 10). A reduc-
tion (F (79, 160) = 11.61, P <0.001) was observed in diacyl
36:1 (18:0/18:1), plasmalogen 36:0 (p18:0/18:0), 36:1
(p18:0/18:1), 36:4 (p16:0/20:4), 38:4 (p18:0/20:4), and 40:6
(p18:0/22:6) molecular species. In contrast, the propor-
tions of polyunsaturated diacyl species (38:4 (18:0/20:4)
and 38:6 (16:0/22:6)) increased with PPA infusions.
Discussion
Behavioral assessment
Locomotor activity as expressed by horizontal, vertical,
and repetitive measures across infusion days was used to
assess abnormal animal behavior. Assessment of loco-
motor activity indicates that PPA infusions induced hyper-
activity and stereotypy in rodents consistent with the
findings from previous studies by our group [7-12]. These
behaviors bear some resemblance to the hyperactive and
repetitive behaviors which are recognized as core symp-
toms of ASD [41]. PPA and other short chain fatty acids
are known to increase intracellular neuronal and glial
acidification and calcium proportions, thereby producing
widespread effects on neurotransmitter release including
glutamate, dopamine, norepinepherine, and serotonin, each
of which play a role in elicitation of locomotor activity, as
seen in the present study [42-44]. In addition, PPA has
been shown to increase glutamatergic transmission, leading
to excitability in brain regions linked to locomotor activity
[45,46]. Collectively, these observations are consistent with
an emerging theory of ASD as a disruption of excitatory/
inhibitory neuronal activity [47]. The fact that PPA infu-
sions consistently induce elevations in locomotor activity
in rodents indicates that this model may be a useful tool
for studying the neurological mechanisms involved in the
behavioral disturbances seen in ASD.
Alterations in phospholipid molecular species
The phospholipid profiles observed in control animals are
consistent with those reported in the literature for rat brain
([48,49]with the exception of SM molecular species. Typic-
ally, molecular species with sphingosine base (C18:1) make
up the largest proportion of the SM profile in mammals. In
this study, molecular species with sphinganine bases
(C18:0) accounted for the largest proportion of rat brain
Table 3 Changes (percent composition) in rat brain phosphatidylcholine molecular species following intraventricular
infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Plasmalogen or diacyl species PBS PPA
706 D30:0 16:0/14:0 0.13 ± 0.055 0.13 ± 0.04
734 D32:0 16:0/16:0 19.23 ± 0.34 19.33 ± 0.69
718 P32:1 p16:0/16:1 0.05 ± 0.01 0.06 ± 0.01
762 D34:0 16:0/18:0 18.66 ± 0.49 19.14 ± 0.63
760 D34:1 16:0/18:1 32.80 ± 0.15 33.68 ± 0.16*
746 P34:1 p16:0/18:1 1.54 ± 0.26 1.40 ± 0.32
758 D34:2 16:0/18:2 0.27 ± 0.04 0.69 ± 0.19*
788 D36:1 18:0/18:1 10.53 ± 0.18 9.20 ± 0.15*
774 P36:1 p18:0/18:1 0.50 ± 0.11 0.40 ± 0.11
782 D36:4 16:0/20:4 3.96 ± 0.51 4.81 ± 0.53*
814 D38:2 18:1/20:1 1.21 ± 0.25 1.29 ± 0.11
812 D38:3 18:0/20:3 1.85 ± 0.28 1.74 ± 0.14
810 D38:4 18:0/20:4 4.91 ± 0.26 4.33 ± 0.34
806 D38:6 16:0/22:6 2.98 ± 0.12 2.74 ± 0.10
834 D40:6 18:0/22:6 1.36 ± 0.11 1.06 ± 0.14
Total% 100 100
P
Saturates 18.78± 0.48 19.27 ± 0.60
P
Monounsat 62.56± 0.51 62.20 ± 0.70
P
Polyunsat 16.55± 0.63 16.65 ± 0.99
P
Plas 2.09 ± 0.32 1.85± 0.43
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species and P represents plasmalogens species, p denotes a sn-1 vinyl ether
(plasmalogen) linkage. Monounsat, monounsaturated fatty acids; PBS, phosphate buffered saline solution; plas, plasmalogens; polyunsat, polyunsaturated fatty
acids; PPA, propionic acid. Phosphatidylcholine molecular species were identified using a precursor ion scan of m/z 184 in ESI positive mode.
Thomas et al. Journal of Neuroinflammation 2012, 9:153 Page 9 of 18
http://www.jneuroinflammation.com/content/9/1/153
Table 5 Changes (percent composition) in rat brain phosphatidylinositol molecular species following intraventricular
infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Diacyl species PBS PPA
835 D34:1 16:0/18:1 0.53 ± 0.05 0.54 ± 0.07
859 D36:3 18:1/18:2 1.01 ± 0.14 0.79 ± 0.01*
857 D36:4 16:0/20:4 7.71 ± 0.32 7.02 ± 0.45
887 D38:3 18:0/20:3 9.07 ± 0.69 9.71 ± 0.73
885 D38:4 18:0/20:4 74.17 ± 1.35 74.60 ± 1.27
883 D38:5 18:1/20:4 5.53 ± 0.73 5.44 ± 0.41
881 D38:6 16:0/22:6 0.80 ± 0.04 0.79 ± 0.04
913 D40:4 18:0/22:4 0.41 ± 0.01 0.17 ± 0.03*
909 D40:6 18:0/22:6 0.77 ± 0.10 0.94 ± 0.12
Total% 100 100
P
Monounsat 0.53 ± 0.05 0.54± 0.07
P
Polyunsat 99.46 ± 0.05 99.46 ± 0.07
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species. Monounsat, monounsaturated fatty acids; PBS, phosphate buffered
saline solution, polyunsat, polyunsaturated fatty acids; PPA, propionic acid. Phosphatidylinositol molecular species were identified using a precursor ion scan of m/
z 241 in ESI negative mode. The lipid components in the table are arranged based on the molecular species composition.
Table 4 Changes (percent composition) in rat plasma phosphatidylcholine molecular species following intraventricular
infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Plasmalogen or diacyl species PBS PPA
706 D30:0 16:0/14:0 0.79 ± 0.42 0.59 ± 0.18
734 D32:0 16:0/16:0 1.39 ± 0.57 2.08 ± 0.14
718 P32:1 p16:0/16:1 0.52 ± 0.39 0.40 ± 0.053
762 D34:0 16:0/18:0 2.90 ± 0.34 3.80 ± 0.32*
760 D34:1 16:0/18:1 9.03 ± 0.73 9.98 ± 1.81
746 P34:1 p16:0/18:1 0.61 ± 0.28 0.52 ± 0.05
758 D34:2 16:0/18:2 20.13 ± 0.23 17.61 ± 0.16*
788 D36:1 18:0/18:1 8.11 ± 0.40 9.87 ± 0.38*
774 P36:1 p18:0/18:1 0.76 ± 0.24 6.24 ± 1.96*
782 D36:4 16:0/20:4 13.23 ± 0.42 11.41 ± 0.22*
814 D38:2 18:1/20:1 4.14 ± 0.24 2.97 ± 0.45*
812 D38:3 18:0/20:3 9.82 ± 2.05 8.70 ± 0.64
810 D38:4 18:0/20:4 23.92 ± 0.41 21.45 ± 0.87*
806 D38:6 16:0/22:6 2.42 ± 0.64 2.60 ± 0.63
834 D40:6 18:0/22:6 2.23 ± 0.68 1.78 ± 0.58
Total% 100 100
P
Saturates 3.68 ± 0.58 4.39± 1.21
P
Monounsat 18.52± 1.57 21.92 ±2.25
P
Polyunsat 75.89± 2.55 66.52 ±2.09*
P
Plas 1.89 ± 0.86 7.15± 1.84*
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species and P represents plasmalogens species, p denotes a sn-1 vinyl ether
(plasmalogen) linkage., Monounsat, monounsaturated fatty acids; PBS, phosphate buffered saline solution; plas, plasmalogens; polyunsat, polyunsaturated fatty
acids; PPA, propionic acid. Phosphatidylcholine molecular species were identified using a precursor ion scan of m/z 184 in ESI positive mode. The lipid
components in the table are arranged based on the molecular species composition.
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SM profile. At this time, we have no suitable/conclusive ex-
planation for this observed variation in brain SM profile
following careful perusal of the data to ensure mass spec-
tral interpretation, data normalization, and calculations are
correct to the best of our knowledge. However, a similar
SM profile with saturated base predominating has been
reported previously in human retina [40].
Phospholipids are the major structural components of
neuronal and other cellular membranes, and include PC,
PE, PS, PI, and SM [50,51]. All of these phospholipid classes
were observed to have altered molecular species distribution
following PPA infusion. It has been suggested that common
neurodevelopmental disorders such as ASD could be asso-
ciated with functional deficiencies or imbalances in fatty acid
Table 7 Changes (nanomole percent by weight composition) in rat brain phosphatidylserine molecular species
following intraventricular infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Diacyl species PBS PPA
760 D34:1 16:0/18:1 0.90 ± 0.10 1.10 ± 0.21
790 D36:0 18:0/18:0 1.59 ± 0.41 1.65 ± 0.11
788 D36:1 18:0/18:1 18.10 ± 0.53 21.62 ± 0.63*
786 D36:2 18:0/18:2 2.36 ± 0.34 2.55 ± 0.17
816 D38:1 18:0/20:1 1.00 ± 0.15 1.22 ± 0.19
810 D38:4 18:0/20:4 4.18 ± 0.07 4.46 ± 0.12
840 D40:3 18:0/22:3 1.19 ± 0.23 1.20 ± 0.17
838 D40:4 18:0/22:4 4.67 ± 0.17 3.63 ± 0.14*
836 D40:5 18:0/22:5 6.40 ± 0.30 6.91 ± 0.43
834 D40:6 18:0/22:6 58.39 ± 0.98 54.49 ± 1.05*
832 D40:7 18:1/22:6 1.22 ± 0.08 1.17 ± 0.12
Total% 100 100
P
Saturates 1.59 ± 0.15 1.65± 0.11
P
Monounsat 19.99 ± 0.39 23.93 ±0.66*
P
Polyunsat 78.41 ± 0.58 74.45 ±0.55*
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species. Monounsat, monounsaturated fatty acids; PBS, phosphate buffered
saline solution; polyunsat, polyunsaturated fatty acids; PPA, propionic acid. Phosphatidylserine molecular species were identified using neutral loss scan of 87 D in
ESI negative mode. The lipid components in the table are arranged based on the molecular species composition.
Table 6 Changes (percent composition) in rat plasma phosphatidylinositol molecular species following intraventricular
infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Diacyl/species PBS PPA
835 D34:1 16:0/18:1 6.71 ± 0.66 9.04 ± 0.39*
859 D36:3 18:1/18:2 6.16 ± 0.29 8.67 ± 0.97*
857 D36:4 16:0/20:4 8.33 ± 1.03 8.70 ± 0.85
887 D38:3 18:0/20:3 8.53 ± 0.63 7.72 ± 0.69
885 D38:4 18:0/20:4 44.00 ± 2.19 32.68 ± 3.6*
883 D38:5 18:1/20:4 6.67 ± 0.56 7.79 ± 0.28
881 D38:6 16:0/22:6 6.17 ± 0.04 7.89 ± 0.50*
913 D40:4 18:0/22:4 6.50 ± 0.60 8.47 ± 0.31*
909 D40:6 18:0/22:6 6.93 ± 0.54 9.04 ± 0.38*
Total% 100 100
P
Monounsat 6.70 ± 0.66 9.03± 1.03
P
Polyunsat 93.29 ± 0.66 90.96 ± 1.03
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species. Monounsat, monounsaturated fatty acids; PBS, phosphate buffered
saline solution, polyunsat, polyunsaturated fatty acids; PPA, propionic acid. Phosphatidylinositol molecular species were identified using a precursor ion scan of
m/z 241 in ESI negative mode. The lipid components in the table are arranged based on the molecular species composition.
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synthesis/metabolism [5,27,29,36]. Most of these former
studies evaluated the fatty acid composition following hy-
drolysis of either total or individual phospholipid classes.
Alterations in specific phospholipid molecular species could
not only contribute more specific clinical criteria, but could
also provide a basis for mechanistic interpretations. How-
ever, to date, only one study [27] has evaluated the intact
phospholipid molecular species in the blood of ASD
patients. Further, these authors only analyzed PE phospho-
lipid molecular species. In the present study, we evaluated
SM, PC, PE, PS, and PI molecular species following infusion
with PPA and the induction of abnormal (ASD-like) beha-
viors. Alterations were observed in 21 brain and 30 blood
phospholipid molecular species. Pastural et al. [27] observed
elevations in the relative proportions of plasmalogen PE,
saturated, and polyunsaturated PE molecular species in the
plasma of ASD patients. In our plasma analyses we also
observed elevations in the relative proportions of polyun-
saturated PE species, but the relative reduction in plasma-
logen PE was in contrast with their findings. In addition,
plasma from PPA-infused rats demonstrated elevations in
the relative proportions of some saturated SM and PC
molecular species, diacyl and plasmalogen monounsatu-
rated PC species, PS monounsaturated species, and some
polyunsaturated PI molecular species (36:3, 40:4, and
40:6). Elevations were also observed in the proportions of
some brain PC polyunsaturated molecular species, PS
monounsaturated, and PE plasmalogen species in the
present study.
Analysis of SM, PC, PI, PE, PS, and PC phospholipid
classes were conducted with both brain and blood sam-
ples. In many cases, the same phospholipid molecular
species were altered in both blood and brain, but the
direction and the relative proportions of these altera-
tions were not consistent between both sample types.
Much of the published work demonstrating alterations
in lipid metabolism in autism has been done using
plasma obtained from ASD patients [5,27,32,36]. The
findings from these studies include elevations in satu-
rated fatty acids [27,29,30], accompanied by a decline in
plasmalogens [5,29,30], mono and polyunsaturated
(ω3 +ω6) fatty acids [5,29,30,32,36,52]. Conversely,
others have reported elevations in the proportions of
mono and poly unsaturated fatty acids [5,27,30,53].
However, the origin of these altered fatty acids and plas-
malogens are unknown, because the structures of the
phospholipids were destroyed by hydrolysis during sam-
ple analysis. This paper is the most comprehensive
study to date which examines intact PL molecular spe-
cies alteration in relation to autism. Currently, there is
no clear uniform mechanism governing the etiology and
early detection of ASD, and no accepted biomarkers are
available. Although this study is descriptive in nature, it
provides considerably more information than is cur-
rently available, and as such provides a foundation for
defining which intact phospholipid molecular species
can be altered in relation to ASD. This could provide a
framework for future studies to elucidate the mechanisms
Table 8 Changes (nanomole percent by weight composition) in rat plasma phosphatidylserine molecular species
following intraventricular infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Diacyl species PBS PPA
762 D34:1 16:0/18:1 6.55 ± 0.30 7.94 ± 0.09*
792 D36:0 18:0/18:0 8.12 ± 0.57 7.62 ± 0.24
790 D36:1 18:0/18:1 9.53 ± 0.74 12.13 ± 1.21*
788 D36:2 18:0/18:2 7.81 ± 0.06 8.84 ± 0.63*
818 D38:1 18:0/20:1 7.72 ± 0.24 6.94 ± 0.63
812 D38:4 18:0/20:4 11.55 ± 1.36 11.76 ± 1.65
842 D40:3 18:0/22:3 8.64 ± 0.53 7.37 ± 0.51*
840 D40:4 18:0/22:4 7.81 ± 0.08 7.50 ± 0.35
838 D40:5 18:0/22:5 7.61 ± 0.23 7.69 ± 0.06
836 D40:6 18:0/22:6 16.67 ± 1.34 13.68 ± 0.88*
834 D40:7 18:1/22:6 7.99 ± 0.37 8.53 ± 0.19
Total% 100 100
P
Saturates 8.12 ± 0.57 7.62± 0.24
P
Monounsat 23.80 ± 1.76 27.02 ±1.99*
P
Polyunsat 68.06 ± 0.99 65.34 ±1.18*
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species. Monounsat, monounsaturated fatty acids; PBS, phosphate buffered
saline solution; polyunsat, polyunsaturated fatty acids; PPA, propionic acid. Phosphatidylserine molecular species were identified using neutral loss scan of 185 D
in ESI positive mode. The lipid components in the table are arranged based on the molecular species composition.
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associated with the observed lipid alterations and their re-
lationship to behavioral changes in ASD.
The use of an animal model allowed comparison of brain
and plasma PL during the period of PPA-induced ASD-like
behaviors. The observations that small amounts (1.04
micromole/infusion) of PPA into brain can influence
plasma lipid composition are considered intriguing. How-
ever, the plasma alterations noted did not correlate directly
with those in brain. It could be that this difference merely
reflects the nature of the PPA rodent model where treat-
ment is limited to 8 days. Furthermore, ASD likely involves
genetic, metabolic, and environmental factors which could
result in systemic as well as CNS effects.
It is evident from the data presented in this study that
PPA infusion produced small but significant alterations in
the composition of brain and plasma phospholipid species.
These alterations occurred independent of diet. The most
notable alterations were observed in the composition of
brain SM, diacyl mono and polyunsaturated PC, PI, PS, PE,
and plasmalogen PC and PE molecular species. These
observations are considered interesting because alterations
in brain lipid composition, particularly during development
can potentially have serious consequences on CNS function.
Potential physiological consequences of altered
phospholipid molecular species and their relation to ASD
Lipid mediated signaling and neuroinflammation in ASD
The pathological consequences of disturbances in phospho-
lipid metabolism could include alterations in signal trans-
duction involving the generation of second messengers
derived from docosahexaenoic (C22:6n3) and arachidonic
(C20:4n6) acids [54]. The observation that PPA infusion
Table 9 Changes (percent composition) in rat brain phosphatidylethanolamine molecular species following
intraventricular infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Plasmalogen or diacyl species PBS PPA
700 P34:1 p16:0/18:1 5.85 ± 0.15 5.10 ± 0.14*
714 D34:2 16:0/18:2 3.37 ± 0.17 3.49 ± 0.15
730 P36:0 p18:0/18:0 3.42 ± 0.13 4.03 ± 0.38
744 D36:1 18:0/18:1 3.50 ± 0.46 3.32 ± 0.37
728 P36:1 p18:0/18:1 6.00 ± 0.09 6.82 ± 0.12*
742 D36:2 18:0/18:2 3.68 ± 0.14 3.59 ± 0.35
726 P36:2 p18:0/18:2 4.79 ± 0.30 7.16 ± 0.62*
724 P36:3 p18:1/18:2 3.38 ± 0.42 2.98 ± 0.27
722 P36:4 p16:0/20:4 4.32 ± 0.12 4.43 ± 0.14
766 D38:4 18:0/20:4 6.99 ± 0.71 7.33 ± 0.62
750 P38:4 p18:0/20:4 6.07 ± 0.13 7.70 ± 0.02*
762 D38:6 16:0/22:6 4.18 ± 0.16 3.45 ± 0.15*
746 P38:6 p16:0/22:6 5.14 ± 0.45 5.11 ± 0.80
796 D40:3 18:0/22:3 3.59 ± 0.26 3.52 ± 0.43
794 D40:4 20:0/20:4 3.51 ± 0.08 3.85 ± 0.42
778 P40:4 p18:0/22:4 3.46 ± 0.26 5.00 ± 0.10*
792 D40:5 18:0/22:5 4.30 ± 0.31 3.93 ± 0.41
776 P40:5 p18:0/22:5 3.91 ± 0.69 3.79 ± 0.60
790 D40:6 18:0/22:6 11.07 ± 1.06 8.59 ± 0.36*
774 P40:6 p18:0/22:6 9.47 ± 0.21 6.82 ± 0.86*
Total% 100 100
P
Saturates 3.42 ± 0.12 4.02± 0.38
P
Monounsat 15.32± 0.65 15.23 ± 0.92
P
Polyunsat 81.23± 0.69 80.73 ± 0.55
P
Plas 55.82± 1.63 58.93 ± 1.40
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species and P represents plasmalogens species, p denotes a sn-1 vinyl ether
(plasmalogen) linkage. Monounsat, monounsaturated fatty acids; PBS, phosphate buffered saline solution; plas, plasmalogens; polyunsat, polyunsaturated fatty
acids; PPA, propionic acid. Phosphatidylethanolamine molecular species were identified using a precursor ion scan of m/z 196 in ESI negative mode. The lipid
components in the table are arranged based on the molecular species composition.
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increased the proportions of brain PI and PC molecular
species containing arachidonic acid and decreased the pro-
portions of PS and PE molecular species with docosahexae-
noic acid, suggests that PPA could influence the innate
neuroinflammatory process observed in autism. Metabol-
ism of arachidonic and docosahexaenoic acids released
from the sn-2 position of the glycerol moiety by phospho-
lipase A2 results in the formation of eicosanoids and
docosanoids, respectively [54]. Both eicosanoids and doco-
sanoids are potent modulators of the inflammatory re-
sponse system. Eicosanoids are inflammatory mediators
that induce the formation of proinflammatory cytokines
such as tumor necrosis factor (TNF), interleukin 1 (IL-1),
and interleukin 6 (IL-6). Elevated levels of TNF, IL-1, and
IL-6 have been reported in plasma of ASD patients [28].
Docosanoids on the other hand are antiflammatory and
include protectins and resolvins that have known
neuroprotective effects [54]. There is now emerging evi-
dence that autism may be accompanied by abnormalities
in the inflammatory response system [28], and that this
abnormality may be related to the increases in oxidative
stress [55-57], innate neuroinflammation [58], and altered
lipid profiles [5,27,30,32,53] reported in ASD.
The increased accumulation of brain molecular species
with the eicosanoids precursor (arachidonic acid), and the
reduced proportions of the molecular species containing
the docosanoids precursor (docosahexaenoic acid) observed
in this study are interesting, considering the increased in-
nate neuroinflammation (reactive astrogliosis and activated
microglia) previously observed with this model [7] and
reported for the brain of ASD patients at autopsy [58].
Several of the studies analyzing the hydrolyzed fatty acid
components obtained from the blood of ASD patients also
report alterations in the proportions of arachidonic and
Table 10 Changes (nanomole percent by weight composition) in rat plasma phosphatidylethanolamine molecular
species following intraventricular infusion with propionic acid (PPA) and phosphate buffered saline (PBS)
Molecular weight Molecular species Plasmalogen or diacyl species PBS PPA
702 P34:1 p16:0/18:1 4.59 ± 0.43 3.51 ± 0.53
716 D34:2 16:0/18:2 4.42 ± 0.13 4.41 ± 0.66
732 P36:0 p18:0/18:0 4.39 ± 0.19 3.11 ± 0.41*
746 D36:1 18:0/18:1 4.55 ± 0.44 3.38 ± 0.49*
730 P36:1 p18:0/18:1 5.76 ± 0.56 3.57 ± 0.50 *
744 D36:2 18:0/18:2 5.20 ± 0.58 4.49 ± 0.55
728 P36:2 p18:0/18:2 3.10 ± 1.36 3.19 ± 0.26
726 P36:3 p18:1/18:2 4.28 ± 0.19 3.85 ± 0.36
724 P36:4 p16:0/20:4 4.47 ± 0.42 3.41 ± 0.46*
768 D38:4 18:0/20:4 10.82 ± 0.71 23.60 ± 4.93*
752 P38:4 p18:0/20:4 4.67 ± 0.06 3.70 ± 0.45*
764 D38:6 16:0/22:6 5.35 ± 0.21 7.02 ± 0.56*
748 P38:6 p16:0/22:6 4.87 ± 0.38 3.71 ± 0.64
798 D40:3 18:0/22:3 4.27 ± 0.34 3.92 ± 0.68
796 D40:4 20:0/20:4 4.78 ± 0.29 3.67 ± 0.62
780 P40:4 p18:0/22:4 4.06 ± 0.17 3.41 ± 0.34
794 D40:5 18:0/22:5 4.97 ± 0.35 4.07 ± 0.32
778 P40:5 p18:0/22:5 4.67 ± 0.27 3.76 ± 0.83
792 D40:6 18:0/22:6 5.89 ± 0.62 7.03 ± 1.63
776 P40:6 p18:0/22:6 4.80 ± 0.33 3.54 ± 0.69*
Total% 100 100
P
Saturates 4.39 ± 0.19 3.11± 0.41*
P
Monounsat 14.92± 0.39 10.46 ±1.46*
P
Polyunsat 80.68± 0.43 86.41 ±1.81*
P
Plas 49.69± 0.96 38.37 ±3.81*
Values (nanomole percent by weight composition) represent means ± standard errors. Means in the same row accompanied by asterisks are significantly different
between treatments at LSD= 0.05, n= 12 per treatment group. D represents diacyl species and P represents plasmalogens species, p denotes a sn-1 vinyl ether
(plasmalogen) linkage. Monounsat, monounsaturated fatty acids; PBS, phosphate buffered saline solution, plas, plasmalogens; polyunsat, polyunsaturated fatty
acids; PPA, propionic acid. Phosphatidylethanolamine molecular species were identified using neutral loss scan of 141 D in ESI positive mode. The lipid
components in the table are arranged based on the molecular species composition.
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docosahexaenoic acids [27,29,32,36]. This could indicate
aberrations in fatty acid elongation and desaturation may
occur in the etiology of ASD. Arachidonic and docosahex-
aenoic acids are cleaved from the sn-2 position of the gly-
cerol moiety by phospholipase A2. Genetic sites linked to
autism on chromosome 8q22 are in the proximity of the
gene (8q24) for secretory phospholipase A2 [36]. Collect-
ively, these findings suggest possible involvements of ara-
chidonate, docosahexaenoate, and phospholipase A2 in the
signal cascade associated with the innate neuroinflamma-
tion observed in ASD.
Membrane fluidity and stability
Biological membranes are predominantly bilayers in which
the inner and outer leaflets have different phospholipid
compositions. In contrast, blood plasma phospholipids are
present as monolayers, sourrounding lipoproteins, and the ef-
fect of fluidity on lipoprotein function is not well understood.
Here we will refer to both cellular bilayers and blood lipopro-
tein monolayers collectively as ‘membranes’. Phospholipid
molecular species distribution influences bilayer physical
properties such as fluidity and this affects membrane pro-
tein function. Monolayer molecular species composition
also affects physical properties. Organisms can adjust the
order or fluidity of their cellular membranes in response to
changes in their physiological environment by altering their
lipid composition [50]. Alterations in brain and blood
phospholipid composition consistent with an adjustment
in the order or fluidity of the membrane in these tissues in
response to PPA infusions were observed in this study.
This adjustment was reflected by changes in the relative
proportions of unsaturated, diacyl, and/or plasmalogen
species. Alterations in desaturation can have profound
changes on membrane fluidity because increased carbon-
carbon double bonds make unsaturated fatty acids more
mobile, flexible, and fluid [50]. Changes in the relative pro-
portions and the composition of diacyl and plasmalogen
forms of phospholipids can also impact the fluidity of the
membrane. For example, plasmalogen species facilitate
membrane fusion six times faster than diacyl species [59].
Phosphatidylcholine, which has a large polar head group
does not pack closely in membrane bilayers and tends to
be more fluid compared to PE, which has a small head
group and packs more closely in membranes, making them
less fluid at physiological temperatures. The PC/PE balance
in cell membranes is thought to regulate membrane fluid-
ity and stabilize the membrane [50,60]. In both brain and
blood membranes, PPA infusions alter the PC and PE
composition (both diacyl and plasmalogen forms) possibly
disrupting this balance. Alterations in brain membrane
lipid composition affecting fluidity have been found to be
associated with a number of behavioral abnormalities, as
well as neurological and psychiatric disorders in both
adults and children [61]. Alterations in membrane fluidity
affect membrane properties, which in turn can affect the
functions of integral membrane proteins, ion channels and
the permeability of solutes across the membrane [54]. It is
unclear at this preliminary stage whether or not any of
these processes are affected by PPA infusion in this model,
or if they are related to the etiology of ASD. These are the
subjects of further studies in our laboratory.
Lipid oxidation/peroxisomal function
Plasmalogens are vinyl ether lipids found in PE, PC and PS.
Several studies have reported increases [27] or declines
[5,29,30] in plasmalogens obtain from the bloods of ASD
patients. Typically plasmalogens have docosahexaenoic or
arachidonic acids esterified in the sn-2 position of the glycerol
moiety, and are essential for normal brain development and
functions. Reduced plasmalogens and docosahexaenoic acid
levels are characteristic of peroxisomal-associated neuro-
logical disorders such as infantile Refsum disease, adreno-
leukodystrophy, adrenomyeloneuropathy, and Zellweger’s
syndrome [5,27,59]. The only study we know that analyzed
the intact PE molecular species of blood obtained from ASD
patients observed an overall increase in PE plasmalogens spe-
cies, and this increase was accompanied by an increase in
docosahexaenoic acid containing molecular species [27]. In
our rat model, we observed an overall reduction in the rela-
tive proportions of PE plasmalogens in plasma, inclusive of
species with docosahexaenoic acid at the sn-2 position of the
glycerol moiety. However, consistent with [27], elevated pro-
portions of PE polyunsaturated diacyl species were observed
in plasma, inclusive of docosahexaenoate containing species.
In brain, a reduction in the relative proportions of diacyl
and plasmalogen PE molecular species containing docosa-
hexaenoic acid was observed in this study following PPA
infusion. This was accompanied by a relative increase in
several other PE plasmalogen molecular species lacking
docosahexaenoic acid in the sn-2 position of the glycerol
moiety. Plasmalogens act as a reservoir for docosahexae-
noic acid, and both compounds have synthetic steps that
occur in the peroxisome, providing a biochemical link [5].
Peroxisomal disorders are characterized by abnormal per-
oxisomal biogenesis associated with altered functionality of
the two rate limiting enzymes in plasmalogen synthesis,
acyl-coenzyme A (CoA): dihydroxyacetonephosphate acyl-
transferase and alkyldihydoxyacetonephosphate synthase
[36,59]. It appears from the findings presented in this study
and those from previous reports [5,27,29,30,52] that aber-
rations in plasmalogen metabolism may occur in ASD, im-
plying that peroxisomal dysfunction could be involved.
Plasmalogens are considered endogenous antioxidants,
because their vinyl ether bonds are efficient neutralizers of
reactive oxygen species, which damage the polyunsaturated
fatty acids present in the sn-2 position of plasmalogen phos-
pholipids [62]. The alterations observed in plasmalogen mo-
lecular species in relation to the alterations in brain and
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blood polyunsaturated PE and PC molecular species, may
be a response to increase oxidation following PPA infusions.
This is very interesting because oxidative damage of lipids
has been suggested to play a part in the pathogenesis of
many neurological diseases including autism [26,55]. In
addition, increased oxidative stress, and decreased antioxi-
dant capacity have been previously reported in this rodent
model [7,8], and also found to be present in ASD patients
[55-57]. Interestingly, oxidative damage has been shown to
uncouple the gap junctions in astrocytes [63,64]. Arachi-
donic and docosahexaenoic acids which are very susceptible
to oxidative damage have been shown to modulate the
coupling capacity of gap junctions [65-67]. In this study,
PPA infusion led to alterations in the proportions of brain
arachidonic and docosahexaenoic acids containing molecu-
lar species.
Collectively, the findings presented in this study, along
with those observed in the blood of ASD patients; indicate
that alterations in peroxisomal associated lipid metabolism
and increased oxidative stress, possibly predisposing poly-
unsaturated fatty acids to oxidative damage may be asso-
ciated with the pathogenesis of ASD.
Conclusion
Infusions with PPA-induced abnormal (ASD-like) behaviors
in rodents consistent with previous studies. This induction
in abnormal behaviors was accompanied by alterations in
several brain and blood SM, PC, PS, PE, and PI molecular
species. Alterations in lipid composition are known to affect
membrane fluidity, peroxisomal functions, gap junction
coupling capacity, and signaling during neuroinflammation,
which may be associated with the pathogenesis of ASD, at
least in a subset of patients. The mechanisms governing
these findings and their potential relevance to the patho-
physiology of ASD, particularly during development, is the
subject of further studies in our laboratory. Finally, these
PPA-induced alterations of brain and plasma phospholipid
molecular species provide further validation of this rodent
model as a useful tool to link the disparate behavioral, cen-
tral nervous system, and systemic findings with a plausible
environmental factor in ASD.
Abbreviations
ASD: Autism spectrum disorder; BUT: Butyric acid; CNS: Central nervous
system; ESI: MS electrospray ionization mass spectrometry;
ICV: Intracerebroventricular; PBS: Phosphate buffered saline;
PC: Phosphatidylcholine; PE: Phosphatidylethanolamine;
PI: Phosphatidylinositol; PPA: Propionic acid; PS: Phosphatidylserine;
PUFA: Polyunsaturated fatty acids; SM: Sphingomyelin.
Competing interests
The authors declare no conflict of interest.
Authors’ contributions
RHT designed and conducted the experiments for the lipid component of
the study and wrote the manuscript. MMM designed and conducted the
experiments for the behavioral component of the study and assisted in
editing the manuscript. JRM assisted with lipid and data analysis and editing
the manuscript. LT assisted with surgery and editing the manuscript. FP co-
supervised the study, assisted with interpretations and editing the
manuscript. SL assisted with electrospray analysis and editing the
manuscript. DFM supervised the study and assisted with editing the
manuscript. All authors discussed the results/ implications, commented on
the manuscript at all stages; read and approved the final manuscript.
Acknowledgements
The authors would like to thank Miss Lisa Huyhn, for her assistance with data
entry. The authors would also like to thank Dr Christopher Guglielmo
(Department of Biology, UWO) for his contribution to data interpretation and
the use of his laboratory space and equipment. This research was supported
by contributions from Goodlife Children’s Foundation and Autism Research
Institute Foundation to Derrick MacFabe. We extend our heartfelt gratitude
to David Patchell-Evans and Kilee Patchell-Evans.
Author details
1The Kilee Patchell-Evans Autism Research Group, Department of Psychology,
University of Western Ontario, London, ON N6A 5C2, Canada. 2Department
of Obstetrics/Gynecology and Biochemistry, University of Western Ontario,
London Health Sciences Center, London, ON, Canada. 3Biological Mass
Spectrometry Laboratory, Department of Biochemistry, University of Western
Ontario, London, ON, Canada.
Received: 8 February 2012 Accepted: 29 May 2012
Published: 2 July 2012
References
1. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M:
Omega-3 fatty acids supplementation in children with autism: a
double-blind randomized, placebo-controlled pilot study. Biol Psychiatry
2007, 61:551–553.
2. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, McTeague M,
Sandler R, Wexler H, Marlowe EM, Collins MD, Lawson PA, Summanen P,
Baysallar M, Tomzynski TJ, Read E, Johnson E, Rolfe R, Nasir P, Shah H, Haake
DA, Manning P, Kaul A: Gastrointestinal microflora studies in late-onset
autism. Clin Infect Dis 2002, 35:S6–S16.
3. Hu VW, Frank BC, Heine S, Lee NH, Quackenbush J: Gene expression
profiling of lymphoblastoid cell lines from monozygotic twins discordant
in severity of autism reveals differential regulation of neurologically
relevant genes. BMC Genomics 2006, 7:118.
4. Sarachana T, Zhou R, Chen G, Manji HK, Hu VW: Investigation of
post-transcriptional gene regulatory networks associated with autism
spectrum disorders by microRNA expression profiling of lymphoblastoid
cell lines. Genome Med 2010, 2:23.
5. Wiest MM, German JB, Harvey DJ, Watkins SM, Hertz-Picciotto I: Plasma
fatty acid profiles in autism: a case–control study. Prostaglandins Leukot
Essent Fatty Acids 2009, 80:221–227.
6. Zerrate MC, Pletnikov M, Connors SL, Vargas DL, Seidler FJ, Zimmerman AW,
Slotkin TA, Pardo CA: Neuroinflammation and behavioral abnormalities
after neonatal terbutaline treatment in rats: implications for autism.
J Pharmacol Exp Ther 2007, 322:16–22.
7. MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F,
Taylor AR, Kavaliers M, Ossenkopp KP: Neurobiological effects of
intraventricular propionic acid in rats: possible role of short chain fatty
acids on the pathogenesis and characteristics of autism spectrum
disorders. Behav Brain Res 2007, 176:149–169.
8. MacFabe DF, Rodriguez-Capote K, Hoffman JE, Franklin AE, Mohammad-Asef Y,
Taylor A, Boon F, Cain DP, Kavaliers M, Possmayer F, Ossenkopp KP: A novel
rodent model of autism: Intraventricular infusions of propionic acid
increase locomotor activity and induce neuroinflammation and oxidative
stress in discrete regions of adult rat brain. Am J Biochem & Biotech. 2008,
4:146–166.
9. MacFabe DF, Cain NE, Boon F, Ossenkopp KP, Cain DP: Effects of the
enteric bacterial metabolic product propionic acid on object-directed
behavior, social behavior, cognition, and neuroinflammation in
adolescent rats: Relevance to autism spectrum disorder. Behav Brain Res
2010, 217:47–54.
10. Shultz SR, MacFabe DF, Martin S, Jackson J, Taylor R, Boon F, Ossenkopp KP,
Cain DP: Intracerebroventricular injections of the enteric bacterial
metabolic product propionic acid impair cognition and sensorimotor
Thomas et al. Journal of Neuroinflammation 2012, 9:153 Page 16 of 18
http://www.jneuroinflammation.com/content/9/1/153
ability in the Long-Evans rat: further development of a rodent model of
autism. Behav Brain Res 2009, 200:33–41.
11. Shultz SR, MacFabe DF, Ossenkopp KP, Scratch S, Whelan J, Taylor R, Cain DP:
Intracerebroventricular injection of propionic acid, an enteric bacterial
metabolic end-product, impairs social behavior in the rat: implications for
an animal model of autism. Neuropharmacology 2008, 54:901–911.
12. Thomas RH, Foley KA, Mepham JR, Tichenoff LJ, Possmayer F, MacFabe DF:
Altered brain phospholipid and acylcarnitine profiles in propionic acid
infused rodents: further development of a potential model of autism
spectrum disorders. J Neurochem 2010, 113:515–529.
13. Mortensen PB, Clausen MR: Short-chain fatty acids in the human colon:
relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl
1996, 216:132–148.
14. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E,
Summanen PH, Granpeesheh D, Dixon D, Liu M, Molitoris DR, Green JA III:
Pyrosequencing study of fecal microflora of autistic and control children.
Anaerobe 2010, 16:444–453.
15. Brock M, Buckel W: On the mechanism of action of the antifungal agent
propionate. Eur J Biochem 2004, 271:3227–3241.
16. Wajner M, Latini A, Wyse AT, Dutra-Filho CS: The role of oxidative damage
in the neuropathology of organic acidurias: insights from animal studies.
J Inherit Metab Dis 2004, 27:427–448.
17. Conn AR, Fell DI, Steele RD: Characterization of alpha-keto acid transport
across blood–brain barrier in rats. Am J Physiol 1983, 245:E253–E260.
18. Karuri AR, Dobrowsky E, Tannock IF: Selective cellular acidification and
toxicity of weak organic acids in an acidic microenvironment. Br J Cancer
1993, 68:1080–1087.
19. Rorig B, Klausa G, Sutor B: Intracellular acidification reduced gap junction
coupling between immature rat neocortical pyramidal neurones.
J Physiol 1996, 490:31–49.
20. DeCastro M, Nankova BB, Shah P, Patel P, Mally PV, Mishra R, La Gamma EF:
Short chain fatty acids regulate tyrosine hydroxylase gene expression
through a cAMP-dependent signaling pathway. Brain Res Mol Brain Res
2005, 142:28–38.
21. Maurer MH, Canis M, Kuschinsky W, Duelli R: Correlation between local
monocarboxylate transporter 1 (MCT1) and glucose transporter 1
(GLUT1) densities in the adult rat brain. Neurosci Lett 2004, 355:105–108.
22. Nakao S, Moriya Y, Furuyama S, Niederman R, Sugiya H: Propionic acid
stimulates superoxide generation in human neutrophils. Cell Biol Int 1998,
22:331–337.
23. Hara H, Haga S, Aoyama Y, Kiriyama S: Short-chain fatty acids suppress
cholesterol synthesis in rat liver and intestine. J Nutr 1999, 129:942–948.
24. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S,
Dupriez V, Vassart G, Van Damme J, Parmentier M, Detheux M: Functional
characterization of human receptors for short chain fatty acids and their role
in polymorphonuclear cell activation. J Biol Chem 2003, 278:25481–25489.
25. Parab S, Nankova BB, La Gamma EF: Differential regulation of the tyrosine
hydroxylase and enkephalin neuropeptide transmitter genes in rat PC12
cells by short chain fatty acids: concentration-dependent effects on
transcription and RNA stability. Brain Res 2007, 1132:42–50.
26. Frye RE, Rossignol DA: Mitochondrial dysfunction can connect the diverse
medical symptoms associated with autism spectrum disorders. Pediatr
Res 2011, 69:41R–47R.
27. Pastural E, Ritchie S, Lu Y, Jin W, Kavianpour A, Khine Su-Myat K, Heath D,
Wood PL, Fisk M, Goodenowe DB: Novel plasma phospholipid
biomarkers of autism: Mitochondrial dysfunction as a putative
causative mechanism. Prostaglandins Leukot Essent Fatty Acids 2009,
81:253–264.
28. Tamiji J, Crawford DA: The neurobiology of lipid metabolism in autism
spectrum disorders. Neurosignals 2010, 18:98–112.
29. Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen AC: Essential
fatty acids and phospholipase A2 in autistic spectrum disorders.
Prostaglandins Leukot. Essent Fatty Acids 2004, 71:201–204.
30. Bell JG, Sargent JR, Tocher DR, Dick JR: Red blood cell fatty acid
compositions in a patient with autistic spectrum disorder: a
characteristic abnormality in neurodevelopmental disorders?
Prostaglandins Leukot. Essent Fatty Acids 2000, 63:21–25.
31. Richardson AJ: Clinical trials of fatty acid treatment in ADHD, dyslexia,
dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty
Acids 2004, 70:383–390.
32. Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D,
Andres C, Chalon S: Plasma fatty acid levels in autistic children.
Prostaglandins Leukot Essent Fatty Acids 2001, 65:1–7.
33. Brugger B, Erben G, Sandhoff R, Wieland FT, Lehmann WD: Quantitative
analysis of biological membrane lipids at the low picomole level by
nano-electrospray ionization tandem mass spectrometry. Proc Natl Acad
Sci U S A 1997, 94:2339–2344.
34. Postle AD, Heeley EL, Wilton DC: A comparison of the molecular species
compositions of mammalian lung surfactant phospholipids. Comp
Biochem Physiol A Mol Integr Physiol 2001, 129:65–73.
35. Pulfer M, Murphy RC: Electrospray mass spectrometry of phospholipids.
Mass Spectrom Rev 2003, 22:332–364.
36. Meguid NA, Atta HM, Gouda AS, Khalil RO: Role of polyunsaturated fatty
acids in the management of Egyptian children with autism. Clin Biochem
2008, 41:1044–1048.
37. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Montreal:
Academic Press; 1986.
38. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and
purification of total lipides from animal tissues. J Biol Chem 1957,
226:497–509.
39. Sherma J, Fried B: Handbook of Thin Layer Chromatography. New York, NY:
Marcel and Dekker; 2003:pp. ii-991.
40. Deeley JM, Mitchell TW, Wei X, Korth J, Nealon JR, Blanksby SJ, Truscott RJ:
Human lens lipids differ markedly from those of commonly used
experimental animals. Biochim Biophys Acta 2008, 1781:288–298.
41. Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A: Autism and pervasive
developmental disorders. J Child Psychol Psychiatry 2004, 45:135–170.
42. Cannizzaro C, Monastero R, Vacca M, Martire M: [3 H]-DA release evoked
by low pH medium and internal H + accumulation in rat hypothalamic
synaptosomes: involvement of calcium ions. Neurochem Int 2003, 43:9–17.
43. Remblier C, Pontcharraud R, Tallineau C, Piriou A, Huguet F: Lactic acid-
induced increase of extracellular dopamine measured by microdialysis in
rat striatum: evidence for glutamatergic and oxidative mechanisms. Brain
Res 1999, 837:22–28.
44. Severson CA, Wang W, Pieribone VA, Dohle CI, Richerson GB: Midbrain
serotonergic neurons are central pH chemoreceptors. Nat Neurosci 2003,
6:1139–1140.
45. Bronstein JM, Farber DB, Wasterlain CG: Regulation of type-II calmodulin
kinase: functional implications. Brain Res Rev 1993, 18:135–147.
46. Nakao S, Fujii A, Niederman R: Alteration of cytoplasmic Ca2+ in resting
and stimulated human neutrophils by short-chain carboxylic acids at
neutral pH. Infect Immun 1992, 60:5307–5311.
47. Fukuchi M, Nii T, Ishimaru N, Minamino A, Hara D, Takasaki I, Tabuchi A,
Tsuda M: Valproic acid induces up- or down-regulation of gene
expression responsible for the neuronal excitation and inhibition in rat
cortical neurons through its epigenetic actions. Neurosci Res 2009,
65:35–43.
48. Bayir H, Tyurin VA, Tyurina YY, Viner R, Ritov V, Amoscato AA, Zhao Q,
Zhang XJ, Janesko-Feldman KL, Alexander H, Basova LV, Clark RS, Kochanek PM,
Kagan VE: Selective early cardiolipin peroxidation after traumatic brain
injury: an oxidative lipidomics analysis. Ann Neurol 2007,
62:154–169.
49. Little SJ, Lynch MA, Manku M, Nicolaou A: Docosahexaenoic acid-induced
changes in phospholipids in cortex of young and aged rats: a lipidomic
analysis. Prostaglandins Leukot Essent Fatty Acids 2007, 77:155–162.
50. Hon GM, Hassan MS, van Rensburg SJ, Abel S, van JP, Erasmus RT, Matsha T:
Red blood cell membrane fluidity in the etiology of multiple sclerosis.
J Membr Biol 2009, 232:25–34.
51. Kakela R, Somerharju P, Tyynela J: Analysis of phospholipid molecular
species in brains from patients with infantile and juvenile neuronal-
ceroid lipofuscinosis using liquid chromatography-electrospray
ionization mass spectrometry. J Neurochem 2003, 84:1051–1065.
52. Bu B, Ashwood P, Harvey D, King IB, Water JV, Jin LW: Fatty acid
compositions of red blood cell phospholipids in children with autism.
Prostaglandins Leukot Essent Fatty Acids 2006, 74:215–221.
53. Sliwinski S, Croonenberghs J, Christophe A, Deboutte D, Maes M:
Polyunsaturated fatty acids: do they have a role in the pathophysiology
of autism? Neuro Endocrinol Lett 2006, 27:465–471.
54. Farooqui AA, Ong WY, Horrocks LA: Biochemical aspects of
neurodegeneration in human brain: involvement of neural membrane
Thomas et al. Journal of Neuroinflammation 2012, 9:153 Page 17 of 18
http://www.jneuroinflammation.com/content/9/1/153
phospholipids and phospholipases A2. Neurochem Res 2004, 29:
1961–1977.
55. Chauhan A, Chauhan V: Oxidative stress in autism. Pathophysiology 2006,
13:171–181.
56. Chauhan A, Chauhan V, Brown WT, Cohen I: Oxidative stress in autism:
increased lipid peroxidation and reduced serum levels of ceruloplasmin
and transferrin–the antioxidant proteins. Life Sci 2004, 75:2539–2549.
57. Chauhan V, Chauhan A, Cohen IL, Brown WT, Sheikh A: Alteration in
amino-glycerophospholipids levels in the plasma of children with
autism: a potential biochemical diagnostic marker. Life Sci 2004, 74:
1635–1643.
58. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA:
Neuroglial activation and neuroinflammation in the brain of patients
with autism. Ann Neurol 2004, 57:67–81.
59. Farooqui AA, Horrocks LA: Plasmalogens, phospholipase A(2), and
docosahexaenoic acid turnover in brain tissue. J Mol Neurosci 2001,
16:263–272.
60. Allen HG, Allen JC, Boyd LC, ston-Mills BP, Fenner GP: Determination of
membrane lipid differences in insulin resistant diabetes mellitus type 2
in whites and blacks. Nutrition 2006, 22:1096–1102.
61. Schuchardt JP, Huss M, Stauss-Grabo M, Hahn A: Significance of long-chain
polyunsaturated fatty acids (PUFAs) for the development and behaviour
of children. Eur J Pediatr 2009, 169:149–164.
62. Gorgas K, Teigler A, Komljenovic D, Just WW: The ether lipid-deficient
mouse: tracking down plasmalogen functions. Biochim Biophys Acta 2006,
1763:1511–1526.
63. Dommels YE, Alink GM, Linssen JP, van OB: Effects of n-6 and n-3
polyunsaturated fatty acids on gap junctional intercellular
communication during spontaneous differentiation of the human colon
adenocarcinoma cell line Caco-2. Nutr Cancer 2002, 42:125–130.
64. Martinez AD, Saez JC: Regulation of astrocyte gap junctions by hypoxia-
reoxygenation. Brain Res Brain Res Rev 2000, 32:250–258.
65. Aylsworth CF, Trosko JE, Welsch CW: Influence of lipids on gap-junction-
mediated intercellular communication between Chinese hamster cells
in vitro. Cancer Res 1986, 46:4527–4533.
66. Champeil-Potokar G, Chaumontet C, Guesnet P, Lavialle M, Denis I:
Docosahexaenoic acid (22:6n-3) enrichment of membrane phospholipids
increases gap junction coupling capacity in cultured astrocytes. Eur J
Neurosci 2006, 24:3084–3090.
67. Rouach N, Avignone E, Meme W, Koulakoff A, Venance L, Blomstrand F,
Giaume C: Gap junctions and connexin expression in the normal and
pathological central nervous system. Biol Cell 2002, 94:457–475.
doi:10.1186/1742-2094-9-153
Cite this article as: Thomas et al.: The enteric bacterial metabolite
propionic acid alters brain and plasma phospholipid molecular species:
further development of a rodent model of autism spectrum disorders.
Journal of Neuroinflammation 2012 9:153.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Thomas et al. Journal of Neuroinflammation 2012, 9:153 Page 18 of 18
http://www.jneuroinflammation.com/content/9/1/153
